Health & Safety Code § 481.1123 — Penalty Group 1-B fentanyl offenses

The statutory text

§ 481.1123 was added to chapter 481 to create a dedicated fentanyl-trafficking offense distinct from the general PG-1 statute under § 481.112. The offense is to knowingly manufacture, deliver, or possess with intent to deliver a controlled substance listed in Penalty Group 1-B.

What Penalty Group 1-B covers

Penalty Group 1-B is defined at § 481.1022 and is narrowly focused on fentanyl, fentanyl analogues, and other potent synthetic opioids identified by chemical structure. Cocaine, heroin, and methamphetamine remain in Penalty Group 1, not 1-B.

The grouping has significant practical effects. PG-1B carries elevated ranges relative to comparable PG-1 weights. The legislature's choice to separate fentanyl reflects the public-safety concern and the per-dose lethality differential.

Weight-based punishment ranges

The aggregate-weight tiers under § 481.1123 mirror the PG-1 structure but at elevated penalties:

Counsel should verify the current text on each case, since the legislature has revisited fentanyl penalty structures in recent sessions.

The fentanyl-specific aggravators

Several aggravators that apply to PG-1 offenses also apply or have parallels in PG-1B prosecutions:

• Drug-free-zone enhancement under § 481.134 — certain ranges of distance from schools, parks, and youth centers.
• "Death or serious bodily injury results" enhancement under § 481.1123(f), in some configurations, where overdose death is attributable to the delivery.
• 3g-list treatment for certain PG-1B offenses, affecting probation eligibility under CCP Art. 42A.054.

The death-resulting enhancement is the most consequential. It requires proof of causation and is increasingly the focus of prosecution theory in PG-1B cases involving overdose fatalities.

Common defense issues

Weight challenges

The aggregate weight includes adulterants and dilutants. Forensic chemists must apportion. Sampling protocol challenges and chain-of-custody issues are commonly litigated.

Knowledge of substance identity

The mens rea is knowledge of possession of a controlled substance, not knowledge of the specific compound. But mistake-of-substance arguments can support mitigation even if not a complete defense.

Possession versus delivery

The "possession with intent to deliver" theory requires more than mere possession. Quantity, packaging, scales, ledgers, and surveillance evidence are the typical proof points. Disputed cases turn on circumstantial inferences.

Confidential-informant attacks

Many PG-1B cases involve CI-driven controlled buys. Discovery of the CI's history, prior cases, and reliability is central.

Search and seizure

Warrants supporting search of residences, vehicles, and storage units are scrutinized under Art. 38.23 in state court. The Texas exclusionary rule is materially more favorable than the federal Leon analysis.

Interaction with federal Controlled Substances Act

Fentanyl trafficking is also prosecuted under 21 U.S.C. § 841, with mandatory minimums keyed to quantity. The federal thresholds for fentanyl are 40 grams (five-year MM) and 400 grams (ten-year MM) in the standard structure, with elevated ranges in "death results" prosecutions under § 841(b)(1)(A).

Dual-jurisdiction analysis is common. Defense counsel should evaluate the suppression posture, sentencing exposure, and cooperation tools under both regimes before forming a forum strategy.

What to do if you are charged

The first 48 hours after arrest are critical. Counsel should:

1. Confirm the controlled-substance lab results and the apportionment protocol.
2. Identify the search and seizure posture and any task-force involvement (which can signal federal interest).
3. Address bond promptly — PG-1B charges produce high initial bonds in most DFW counties.
4. Evaluate whether cooperation is available and on what terms, where appropriate to the case.

Forensic-chemistry challenges in PG-1B cases

The State must prove the substance is a PG-1B controlled substance by competent forensic-chemistry evidence. Defense challenges typically focus on:

1. Sampling protocols. When multiple bags or pills are seized, the lab does not typically test every unit. The sampling protocol must support the inference that untested units are also PG-1B.
2. Instrument calibration. Gas chromatography-mass spectrometry instruments require routine calibration. Records can be subpoenaed.
3. Chain of custody. The path from seizure to lab to courtroom must be documented. Gaps can support a motion to suppress or exclude.
4. Analyst availability. Under the Confrontation Clause, the analyst who performed the testing must be available for cross-examination.

Defense forensic experts can review the lab's protocols, calibration records, and analyst notes. The defense expert's analysis sometimes identifies discrepancies that lead to dismissal or charge reduction before trial.

The "death results" enhancement and causation

The "death results" enhancement for fentanyl delivery presents a causation question that has been litigated in federal cases and increasingly in Texas. The federal standard in Burrage v. United States requires "but-for" causation — the controlled substance must be a but-for cause of death.

Texas case law has generally followed the federal causation framework. The defense expert (toxicologist or forensic pathologist) can address whether the decedent had other substances in the system, whether fentanyl was the necessary cause, and whether the decedent's pre-existing medical conditions contributed to the cause of death.

Defense investigation in a "death results" case should include:

• The medical examiner's autopsy report and tox screen.
• The decedent's medical history.
• Evidence of other substances or alcohol consumption.
• Time-of-ingestion analysis.
• Whether the alleged delivery was the source of the substance that caused death.

Sentencing-phase mitigation in PG-1B cases

For defendants who plead or are convicted in a PG-1B case, the sentencing phase carries substantial weight given the elevated punishment ranges. Effective sentencing-phase mitigation includes:

1. Substance-use evaluation. A clinical evaluation that distinguishes addiction from trafficking-driven conduct supports treatment-based dispositions.
2. Mental-health evaluation. Co-occurring mental-health diagnoses (depression, PTSD, opioid-use disorder) support treatment focus and may reduce predicted future dangerousness.
3. Employment and family stability. Letters from employers, family members, faith-community leaders, and treatment providers build the personal-history record.
4. Treatment-engagement evidence. Documented engagement in outpatient or inpatient substance-use treatment before sentencing demonstrates rehabilitation potential.
5. Restitution and recovery work. For defendants whose offenses caused harm, restitution payments and harm-reduction work are quantifiable mitigation.

The Texas sentencing process does not have a structured presentence report comparable to the federal PSR, but the trial court can consider any information relevant to sentencing under Art. 37.07 § 3(a). A well-prepared mitigation packet often produces lower sentences than the unmitigated case would suggest.

Engaging counsel and next steps

PG-1B prosecutions are among the most punitive drug cases under Texas law. The statutory ranges are elevated relative to other penalty groups, and the death-results enhancement adds an additional layer of risk. Counsel handling these cases works against a tight statutory framework.

The DFW criminal-defense landscape has evolved substantially in the post-pandemic period. Caseloads have shifted, prosecutor staffing has changed, and several core statutes have been amended by the 88th and 89th Legislatures. Counsel should periodically refresh the working knowledge base — bar CLE materials, the Texas District & County Attorneys Association publications, and the Court of Criminal Appeals' recent opinions are reliable starting points.

For defendants facing a § 481.1123 charge, the first 30-60 days set the trajectory. Bond setting, forum analysis (state versus federal), and forensic-chemistry review of the lab results are all critical early-stage tasks.

For potential clients in Collin, Dallas, Denton, Tarrant, Rockwall, Kaufman, Ellis, Johnson, and Hunt counties, consultations at L and L Law Group are free and confidential. The earlier counsel is engaged, the more strategic options remain open. Many of the procedural levers discussed in this article narrow or close as the case progresses; an attorney engaged at the magistrate stage has tools that an attorney engaged at sentencing does not.

Final framework: how counsel approaches a PG-1B case

A working framework for § 481.1123 cases:

1. Initial intake (week one). Bond, basic discovery, charging review, forum analysis.
2. Forensic review (weeks 2-6). Lab results, sampling protocol, chain of custody, defense expert engagement.
3. Causation analysis if "death results" charged (weeks 4-8). Autopsy report, tox screen, defense forensic pathologist or toxicologist.
4. Disposition strategy (ongoing). Deferred adjudication, treatment-court referral, plea negotiation, trial preparation.
5. Sentencing preparation (final phase). Mitigation evidence, treatment engagement, family and community letters.

Charging-decision indicators for PG-1B cases

Counsel evaluating a PG-1B case from the defense side should pay close attention to charging indicators that signal the State's theory of the case:

• Aggregate weight charged. The specific weight tier signals the State's view on the trafficking-versus-personal-use spectrum.
• Inclusion of "with intent to deliver" language. Possession-only charging is different from possession-with-intent-to-deliver charging.
• Drug-free zone enhancement allegation. Triggers the 1,000-foot rule under § 481.134.
• Death-results enhancement allegation. Signals the State has evidence of causation, typically from a medical-examiner report.
• Conspiracy or aggregation theories. The State may aggregate multiple seizures across time or location to push into a higher weight tier.
• Federal task-force involvement. Signals possible federal adoption of the case.

Each indicator changes the case posture and the realistic disposition options. Counsel should map the indicators at intake and update the analysis as discovery develops.

Sentencing-mitigation specifics for first-time PG-1B defendants

First-time defendants facing PG-1B charges should develop a mitigation record that addresses:

• The defendant's personal substance-use history, distinguishing addiction from trafficking.
• Treatment engagement before sentencing (outpatient or residential).
• Employment history and current employment status.
• Family responsibilities, particularly for defendants with minor children or dependent elderly relatives.
• Educational background and ongoing educational engagement.
• Community-support letters from non-criminal-justice contacts.
• Mental-health diagnosis and treatment where applicable.
• Any documented harm reduction or restitution efforts.

For first-time defendants in lower weight tiers, a robust mitigation record can support deferred adjudication or a low-range sentence. For higher-tier or repeat-offender cases, mitigation supports the negotiated outcome and the parole-board work that follows incarceration.

References

1. Texas Health and Safety Code § 481.1123 (manufacture or delivery, Penalty Group 1-B), statutes.capitol.texas.gov/Docs/HS/htm/HS.481.htm.
2. Texas Health and Safety Code § 481.1022 (Penalty Group 1-B), statutes.capitol.texas.gov/Docs/HS/htm/HS.481.htm.
3. 21 U.S.C. § 841 (federal Controlled Substances Act trafficking offenses), law.cornell.edu/uscode/text/21/841.